MX375324B - Anticuerpos contra determinantes de la superficie de s. aureus. - Google Patents

Anticuerpos contra determinantes de la superficie de s. aureus.

Info

Publication number
MX375324B
MX375324B MX2015005477A MX2015005477A MX375324B MX 375324 B MX375324 B MX 375324B MX 2015005477 A MX2015005477 A MX 2015005477A MX 2015005477 A MX2015005477 A MX 2015005477A MX 375324 B MX375324 B MX 375324B
Authority
MX
Mexico
Prior art keywords
antibodies
aureus
binding fragments
antibodies against
against surface
Prior art date
Application number
MX2015005477A
Other languages
English (en)
Other versions
MX2015005477A (es
Inventor
Bret Sellman
Chew-Shun Chang
Christine Tkaczyk
Hua Lei
Partha S Chowdhury
Peter Pavlik
Rebecca Buonpane
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2015005477A publication Critical patent/MX2015005477A/es
Publication of MX375324B publication Critical patent/MX375324B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen anticuerpos y fragmentos de unión al antígeno de estos dirigidos contra determinantes antigénicos de la superficie Staphylococcus aureus (S. aureus) y toxinas secretadas. También se proporcionan métodos para detectar, diagnosticar y tratar S. aureus empleando los anticuerpos y fragmentos de unión al antígeno de estos.
MX2015005477A 2012-11-06 2013-11-06 Anticuerpos contra determinantes de la superficie de s. aureus. MX375324B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261723137P 2012-11-06 2012-11-06
US201361782405P 2013-03-14 2013-03-14
PCT/US2013/068624 WO2014074540A2 (en) 2012-11-06 2013-11-06 Antibodies to s. aureus surface determinants

Publications (2)

Publication Number Publication Date
MX2015005477A MX2015005477A (es) 2015-11-30
MX375324B true MX375324B (es) 2025-03-06

Family

ID=50685304

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015005477A MX375324B (es) 2012-11-06 2013-11-06 Anticuerpos contra determinantes de la superficie de s. aureus.
MX2022008079A MX2022008079A (es) 2012-11-06 2015-04-29 Anticuerpos contra determinantes de la superficie de s. aureus.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022008079A MX2022008079A (es) 2012-11-06 2015-04-29 Anticuerpos contra determinantes de la superficie de s. aureus.

Country Status (16)

Country Link
US (3) US9879070B2 (es)
EP (2) EP3640338A1 (es)
JP (2) JP6694269B2 (es)
KR (1) KR102288394B1 (es)
CN (2) CN104968797B (es)
AU (2) AU2013341361A1 (es)
BR (1) BR112015010125A2 (es)
CA (1) CA2890427C (es)
DK (1) DK2917360T3 (es)
ES (1) ES2776179T3 (es)
HU (1) HUE049012T2 (es)
MX (2) MX375324B (es)
PL (1) PL2917360T3 (es)
RU (1) RU2698131C2 (es)
SG (2) SG10201703678TA (es)
WO (1) WO2014074540A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX375113B (es) * 2011-02-08 2025-03-04 Medimmune Llc Anticuerpos que se unen específicamente a la toxina alfa de staphylococcus aureus y métodos de uso.
JP6058645B2 (ja) 2011-06-10 2017-01-11 メディミューン，エルエルシー 抗シュードモナス属（Ｐｓｅｕｄｏｍｏｎａｓ）Ｐｓｌ結合分子およびその使用
SMT202000542T1 (it) * 2011-11-07 2020-11-10 Medimmune Ltd Terapie di combinazione utilizzando molecole di legame anti-psl e pcrv di pseudomonas
EP2793944B1 (en) 2011-12-23 2025-10-08 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
DK2917360T3 (da) * 2012-11-06 2020-03-30 Medimmune Llc Antistoffer mod S. aureus-overflade-determinanter
CN112316135A (zh) 2012-11-06 2021-02-05 米迪缪尼有限公司 治疗金黄色葡萄球菌相关疾病的方法
KR101753553B1 (ko) * 2014-06-03 2017-07-03 엑스바이오테크, 인크. 스타필로코커스 아우레우스 감염의 치료 및 예방을 위한 조성물 및 방법
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
EP3180620B1 (en) * 2014-08-12 2020-01-01 X4 Pharmaceuticals (Austria) GmbH Predicting s. aureus disease
WO2016073860A1 (en) * 2014-11-06 2016-05-12 Medimmune, Llc Binding molecules specific for staphylococcus protein a and uses thereof
FR3033333A1 (fr) * 2015-03-06 2016-09-09 Commissariat Energie Atomique Procede et dispositif pour detecter en temps reel un compose secrete et la cible secretrice ainsi que leurs utilisations
KR20170136637A (ko) * 2015-04-17 2017-12-11 알사니스 바이오사이언시스 게엠베하 항-스타필로코커스 아우레우스 항체 배합 제제
US20190077851A1 (en) * 2015-10-30 2019-03-14 Bruno Francois Methods of using anti-alpha toxin antibody
CN105424930A (zh) * 2015-11-23 2016-03-23 天津科技大学 一种快速检测金黄色葡萄球菌的方法
CN111148758B (zh) * 2017-09-29 2022-12-09 瑞泽恩制药公司 结合葡萄球菌属靶抗原和补体成分的双特异性抗原结合分子及其用途
CA3107463A1 (en) 2018-07-24 2020-01-30 Medimmune, Llc Antibody directed against s. aureus clumping factor a (clfa)
CN113164602A (zh) 2018-10-09 2021-07-23 免疫医疗有限责任公司 抗金黄色葡萄球菌抗体的组合
JP7459075B2 (ja) 2018-10-09 2024-04-01 メディミューン，エルエルシー スタフィロコッカス・アウレウス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）ロイコトキシンに対して向けられた抗体
EP3923978A1 (en) 2019-02-12 2021-12-22 Regeneron Pharmaceuticals, Inc. Compositions and methods for using bispecific antibodies to bind complement and a target antigen
CN113811544A (zh) 2019-03-13 2021-12-17 免疫医疗有限责任公司 减少定殖患者中的金黄色葡萄球菌感染
WO2020210650A1 (en) 2019-04-12 2020-10-15 Medimmune, Llc Neutralization of tgf-beta or alpha-v-beta-8 integrin for s. aureus infections
CN112538112B (zh) * 2019-09-20 2023-10-27 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用
KR102397684B1 (ko) * 2019-12-09 2022-05-13 (주)옵토레인 항체의 항원 결합 부위에 결합하는 펩티드 및 이를 이용한 분석 방법
KR102504175B1 (ko) * 2020-06-17 2023-02-28 (주)옵토레인 항체의 항원 결합 부위에 결합하는 펩타이드, 이를 이용한 약물 복합체, 바이오센서 및 분석 방법
KR102674109B1 (ko) * 2021-01-14 2024-06-12 (주)옵토레인 스위칭 펩티드, 이를 포함하는 면역분석 장치 및 이를 이용한 면역분석 방법
KR102674098B1 (ko) * 2021-01-14 2024-06-12 (주)옵토레인 스위칭 펩티드 및 이를 이용한 멀티플렉스 면역분석 방법
KR102674120B1 (ko) * 2021-01-18 2024-06-12 (주)옵토레인 스위칭 펩티드 및 이를 이용한 면역분석 방법

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2017198A (en) * 1931-10-17 1935-10-15 Anglada Motor Corp Cuff valve engine
US20030044772A1 (en) * 1997-08-04 2003-03-06 Applied Molecular Evolution [Formerly Ixsys] Methods for identifying ligand specific binding molecules
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US7214786B2 (en) * 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
WO2002072600A2 (en) * 2001-01-26 2002-09-19 Inhibitex, Inc. Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections
US7604799B2 (en) * 2003-06-06 2009-10-20 Medimmune, Llc EphA4 Antibodies
CA2535171A1 (en) 2003-08-12 2005-03-03 Dyax Corp. Tie1-binding ligands
WO2006017538A2 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
US20080050361A1 (en) * 2004-10-25 2008-02-28 Heinrichs David E Staphylococcus aureas specific anti-infectives
AU2007222798A1 (en) 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
US7910703B2 (en) * 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
CN101466406B (zh) * 2006-06-12 2012-06-27 葛兰素史密斯克蓝生物品公司 α-毒素在治疗和预防葡萄球菌感染上的用途
WO2008152447A2 (en) * 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
US9526774B1 (en) * 2006-11-06 2016-12-27 Microvax, Llc Methods and compositions for suppressing virulence of methicillin resistant Staphylococcus aureus
MX2010008423A (es) * 2008-01-31 2010-09-22 Trinity College Dublin Tratamiento de infecciones microbianas.
EP2291196A4 (en) * 2008-05-12 2012-05-30 Strox Biopharmaceuticals Llc FOR STAPHYLOCOCCUS AUREUS SPECIFIC ANTIBODY PREPARATIONS
WO2010005513A2 (en) * 2008-06-30 2010-01-14 The Texas A&M University System Crystal structure of staphylococcus aureus clumping factor a in complex with fibrinogen derived peptide and uses thereof
WO2010042481A1 (en) * 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
WO2011019423A2 (en) * 2009-05-20 2011-02-17 Schering Corporation Modulation of pilr receptors to treat microbial infections
MX343111B (es) * 2009-06-22 2016-10-25 Wyeth Llc Composiciones inmunogenicas de antigenos de staphylococcus aureus.
CN102666583B (zh) * 2009-07-15 2015-11-25 Aimm医疗股份公司 革兰氏阳性细菌特异性结合化合物
GB0913680D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2284193A1 (en) * 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
US20130052195A1 (en) * 2009-12-23 2013-02-28 Emergent Product Development Seattle,LLC Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof
EP2555794A4 (en) * 2010-04-05 2014-01-15 Univ Chicago COMPOSITIONS AND METHODS RELATING TO PROTEIN A (SPA) ANTIBODIES AS IMMUNE REACTION AMPLIFIERS
EP2614074A1 (en) * 2010-09-09 2013-07-17 The University of Chicago Methods and compositions involving protective staphylococcal antigens
US20120202047A1 (en) 2011-02-07 2012-08-09 Baker Hughes Incorporated Nano-coatings for articles
MX375113B (es) * 2011-02-08 2025-03-04 Medimmune Llc Anticuerpos que se unen específicamente a la toxina alfa de staphylococcus aureus y métodos de uso.
CN103906535B (zh) * 2011-08-15 2017-07-14 芝加哥大学 与葡萄球菌蛋白a的抗体相关的组合物和方法
PL2794905T3 (pl) * 2011-12-20 2020-11-02 Medimmune, Llc Zmodyfikowane polipeptydy dla rusztowań przeciwciał dwuswoistych
WO2013162746A1 (en) * 2012-04-26 2013-10-31 University Of Chicago Staphylococcal coagulase antigens and methods of their use
DK2917360T3 (da) * 2012-11-06 2020-03-30 Medimmune Llc Antistoffer mod S. aureus-overflade-determinanter
CN112316135A (zh) * 2012-11-06 2021-02-05 米迪缪尼有限公司 治疗金黄色葡萄球菌相关疾病的方法
WO2014127200A1 (en) * 2013-02-15 2014-08-21 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
WO2015057893A2 (en) * 2013-10-15 2015-04-23 The Texas A&M University System Compositions and the use of a fibrinogn binding motif presence in efb and coa for vaccine against staphylococcus aureus and drug delivery
US20170023569A1 (en) * 2014-01-10 2017-01-26 University Of Rochester Diagnostic device and method for detection of staphylococcus infection
WO2015112895A2 (en) * 2014-01-24 2015-07-30 Church William R Antibody specific to staphylococcus aureus, therapeutic method and detection method using same
KR101753553B1 (ko) * 2014-06-03 2017-07-03 엑스바이오테크, 인크. 스타필로코커스 아우레우스 감염의 치료 및 예방을 위한 조성물 및 방법
TWI719938B (zh) * 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
WO2016073860A1 (en) * 2014-11-06 2016-05-12 Medimmune, Llc Binding molecules specific for staphylococcus protein a and uses thereof
KR20170136637A (ko) 2015-04-17 2017-12-11 알사니스 바이오사이언시스 게엠베하 항-스타필로코커스 아우레우스 항체 배합 제제
US20190077851A1 (en) * 2015-10-30 2019-03-14 Bruno Francois Methods of using anti-alpha toxin antibody
US11596699B2 (en) * 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
BR112018077540A2 (pt) * 2016-07-08 2019-10-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services vírus quimérico da dengue/zika como vacinas de zika vírus vivo atenuado
CA3107463A1 (en) 2018-07-24 2020-01-30 Medimmune, Llc Antibody directed against s. aureus clumping factor a (clfa)
CN113164602A (zh) * 2018-10-09 2021-07-23 免疫医疗有限责任公司 抗金黄色葡萄球菌抗体的组合
JP7459075B2 (ja) * 2018-10-09 2024-04-01 メディミューン，エルエルシー スタフィロコッカス・アウレウス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）ロイコトキシンに対して向けられた抗体
CN113811544A (zh) * 2019-03-13 2021-12-17 免疫医疗有限责任公司 减少定殖患者中的金黄色葡萄球菌感染

Also Published As

Publication number Publication date
US20190016787A1 (en) 2019-01-17
AU2018241107B2 (en) 2020-09-17
PL2917360T3 (pl) 2020-06-29
EP2917360B1 (en) 2020-01-08
KR102288394B1 (ko) 2021-08-09
WO2014074540A2 (en) 2014-05-15
ES2776179T3 (es) 2020-07-29
US11447543B2 (en) 2022-09-20
CA2890427A1 (en) 2014-05-15
AU2013341361A1 (en) 2015-06-04
DK2917360T3 (da) 2020-03-30
CN109553681A (zh) 2019-04-02
AU2018241107A1 (en) 2018-10-25
MX2015005477A (es) 2015-11-30
HK1215054A1 (en) 2016-08-12
US20200407429A1 (en) 2020-12-31
US10730934B2 (en) 2020-08-04
JP6694269B2 (ja) 2020-05-13
MX2022008079A (es) 2022-07-11
RU2698131C2 (ru) 2019-08-22
RU2015121624A (ru) 2016-12-27
EP3640338A1 (en) 2020-04-22
HK1215452A1 (zh) 2016-08-26
SG11201503232TA (en) 2015-05-28
EP2917360A4 (en) 2017-01-25
CN104968797B (zh) 2018-11-30
US20150291685A1 (en) 2015-10-15
SG10201703678TA (en) 2017-06-29
CN104968797A (zh) 2015-10-07
US9879070B2 (en) 2018-01-30
WO2014074540A3 (en) 2014-07-10
KR20150094621A (ko) 2015-08-19
JP2019089801A (ja) 2019-06-13
HUE049012T2 (hu) 2020-09-28
BR112015010125A2 (pt) 2017-08-22
JP2016507470A (ja) 2016-03-10
RU2019122610A (ru) 2020-02-18
EP2917360A2 (en) 2015-09-16
CA2890427C (en) 2022-05-31

Similar Documents

Publication Publication Date Title
MX375324B (es) Anticuerpos contra determinantes de la superficie de s. aureus.
WO2015112805A8 (en) Human antibodies to pd-l1
PH12018501611A1 (en) Antigen binding proteins thant bind pd-l1
EA201001335A1 (ru) Антитела, направленные против ангиопоэтина-1 и ангиопоэтина-2, и их применение
PH12017500890A1 (en) Antibody drug conjugates
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
DOP2013000129A (es) PROTEÍNAS DE UNIÓN AL TNF-a.
EA201790757A1 (ru) Связывающие антиген cd27l белки
EP4491195A3 (en) Bispecific tetravalent antibodies and methods of makiing and using thereof
NZ706377A (en) Il-6 antagonists and uses thereof
NZ629296A (en) Humanized antibodies that recognize alpha-synuclein
EA202091315A2 (ru) Антитела человека, связывающиеся с g-белком rsv
MX392098B (es) Anticuerpos neutralizantes de poliomavirus.
MX2020009700A (es) Anticuerpos que se unen especificamente a la toxina alfa de staphylococcus aureus y metodos de uso.
WO2012135740A3 (en) Cd37-binding molecules and immunoconjugates thereof
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
MX395257B (es) Anticuerpos para cd40.
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
WO2014200898A3 (en) Cmv neutralizing antigen binding proteins
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
EA201491575A1 (ru) Антитела к матриксной металлопротеиназе 9
MX2015008117A (es) Anticuerpos anti-h7cr.

Legal Events

Date Code Title Description
FG Grant or registration